CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
CSP01 +2 moredevice
Likely dose
Three capsules of CSP01 in the morning before breakfast and three capsules at night before dinner for three weeks (total 6 capsules daily)AI-extracted
Key inclusion· 5
  • Age 22 to 70 years
  • BMI between 18.5 and 35 kg/m²
  • Meets Rome III criteria for functional constipation or IBS-C
  • Confirmed constipation during 7-day run-in: <3 continuous spontaneous bowel movements per week AND ≤6 spontaneous bowel movements per week
Key exclusion· 19
  • History of loose stools, watery stools, or IBS with diarrhea/mixed IBS
  • Watery stools (Type 7 Bristol Stool Form Scale) or loose/mushy stools >1 per week during run-in
  • Current or recent opioid use (prescription or illicit)
  • History of pelvic floor dysfunction or need for manual maneuvers to achieve bowel movement

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03054506
NCT03054506N/ACompleted

A Randomized, Single Center, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

Massachusetts General Hospital·interventional·Posted Feb 15, 2017·Updated Aug 20, 2019

In Brief

A clinical study evaluating CSP01, Carboxymethylcellulose (CMC), and 1 other intervention for Constipation and 2 related conditions. Completed, enrolled 52 participants across 1 site.

Detailed Summary

Constipation is a common gastrointestinal motility disorder that is often chronic, negatively affects patients' daily lives. Constipation occurs when bowel movements become difficult or less frequent.This study is being done to study the effectiveness of the hydrogel capsule, CSP01, compared to the active control (carboxymethylcellulose) and placebo (non-medicine sugar pill), to relieve constipation among subjects with chronic idiopathic constipation (CIC) or with irritable bowel syndrome with constipation (IBS-C).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGelesis, Inc.

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 15, 2017
Enrollment StartMar 7, 2017
Primary CompletionMay 10, 2018
Study CompletionFeb 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.4 years ago

Interventions

CSP01device

Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.

Carboxymethylcellulose (CMC)device

Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.

Placebodevice

Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.